- FibroGen (NASDAQ:FGEN) is up 2% after hours on the heels of its announcement of positive results from a Phase 2b clinical trial, PRAISE, evaluating pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). The data were presented at the American Thoracic Society Conference in San Diego.
- At week 24, the change from baseline in quantitative lung fibrosis (QLF) volume in the treatment group was 24.8 mL compared to 86.4 mL for placebo (p=0.0090) (the lower number indicates less fibrosis). At week 48, the QLF change from baseline was 75.4 mL in the pamrevlumab group versus 151.5 mL for placebo (p=0.038).
- Phase 3-stage pamrevlumab is a fully human monoclonal antibody that binds to (inhibits) the activity of connective tissue growth factor (CTGF), a protein that plays a key role in the progression of fibrosis (scarring) and related diseases.